Pharmacology of vasoactive drugs
DOI:
https://doi.org/10.11606/issn.2317-0190.v17i1a103306Keywords:
Peripheral Vascular Diseases, Pharmacology, Review Literature as TopicAbstract
Peripheral vascular diseases (PVDS) are characterized as a circulation problem in the veins, arteries, and lymphatic system. The main therapy consists of changes in lifestyle such as diet and physical activity. The pharmacological therapy includes the use of vasoactive drugs, which are used in arteriopathies and venolymphatic disorders. The goal of this study was to research the scientific literature on the use and pharmacology of vasoactive drugs, emphasizing the efficacy of their local actions and administration.
Downloads
References
Oales JA, Brown NJ. Treatment of myocardial ischemia. In: Hardmons J. Goodman and Gillman's the pharmacologic basis of therapeutics. 11th ed. Columbus, OH: McGraw Hill; 2006. p. 871.
Rang HP, Dale MM, Ritter JM, Flower RJ. Farmacologia. 6th. Rio de Janeiro: Elsevier; 2007.
Stücker M, Falkenberg M, Reuther T, Altmeyer P, Lübbers DW. Local oxygen content in the skin is increased in chronic venous incompetence. Microvasc Res. 2000;59(1):99-106.
Araújo M. Drogas que visam agir na circulação periférica. In: Silva P. Farmacologia. Rio de Janeiro: Guanabara Koogan; 2002. p.682-8.
Dominguez-Jimenez C, Sancho D, Nieto M, Montoya Maria C, Barreiro O, Sanchez-Madrid F, et al. Effect of pentoxifylline on polarization and migration of human leukocytes. J Leukoc Biol. 2002;71(4):588-96.
Jacoby D, Mohler ER III. Drug Treatment of Intermittent Claudication. Drugs. 2004;64(15):1657-70.
Dorazil-Dudzik M, Mika J, Schafer MK-H, Li Y, Obara I, Wordliczek J, et al. The Effects of Local Pentoxifylline and Propentofylline Treatment on Formalin-Induced Pain and Tumor Necrosis Factor-Messenger RNA Levels in the Inflamed Tissue of the Rat Paw. Anesth Analg. 2004;98(6):1566-73.
Wordliczek J, Szczepanik AM, Banach M, Turchan J, Zembala M, Siedlar M, et al. The effect of pentoxifiline on post - injury hyperalgesia in rats and postoperative pain in patients. Life Sci. 2000;66(12):1155-64.
Wollina U, Abdel-Naser MB, Mani R. A Review of the microcirculation in skin in patients with chronic venous insufficiency: The problem and the evidence available for therapeutic options. Int J Low Extrem Wounds. 2006;5(5):169-80.
Conte MS. Buflomedil in peripheral arterial disease: trials and tribulations. Circulation. 2008;117(6):717-9
De Backer TL, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database Syst Rev. 2008;(1):CD000988.
Conners MS, Money SR. Can claudication be improved with medication? Semin Vasc Surg. 2002;15(4):237-44.
Tiwary AK, Sapra B, Jain S. Innovations in transdermal drug delivery: formulations and techniques. Recent Pat Drug Deliv Formul. 2007;1(1):23-36.
Ahad A, Aqil M, Kohli K, Chaudhary H, Sultana Y, Mujeeb M, et al. Chemical penetration enhancers: a patent review. Expert Opin Ther Pat. 2009;19(7):969-88.
Nounou MI, El-Khordagui LK, Khalafallah NA, Khalil SA. Liposomal formulation for dermal and transdermal drug delivery: past, present and future. Recent Pat Drug Deliv Formul. 2008;2(1):9-18.
Rizwan M, Aqil M, Talegaonkar S, Azeem A, Sultana Y, Ali A. Enhanced transdermal drug delivery techniques: an extensive review of patents. Recent Pat Drug Deliv Formul. 2009;3(2):105-24.
Roesken F, Uhl E, Curri SB, Menger MD, Messmer K. Acceleration of wound healing by topical drug delivery via liposomes. Langenbecks Arch Surg. 2000;385(1):42-9.
Uhl E, Rösken F, Curri SB, Menger MD, Messmer K. Reduction of skin flap necrosis by transdermal application of buflomedil bound to liposomes. Plast Reconstr Surg. 1998;102(5):1598-604.
Wichers IM, Di Nisio M, Büller HR, Middeldorp S. Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review. Haematologica. 2005;90(5):672-7.
Superficial Thrombophlebitis Treated By Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med. 2003;163(14):1657-63.
Jones H, Paul W, Page CP. The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin. Br J Pharmacol. 2002;135(2):469-79.
Metsavaht L, Metsavaht O, Metsavaht R. Mesoterapia anátomo-clínica na dor músculo-esquelética. In: Teixeira MJ. Dor: contexto interdisciplinar. Curitiba: Maio: 2003. p. 673-88.
Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging. 2007;2(3):327-35.
Gomaa A, Eissa M, El-Gebaley A. The effect to topically applied vasoactive agents and testosterone versus testosterone in the treatment of erectile dysfunction in aged men with low sexual interest. Int J Impot Res. 2001;13(2):93-9.
Gomaa A, Shalaby M, Osman M, Eissa M, Eizat A, Mahmoud M, et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. BMJ. 1996;312(7045):1512-5.
Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol. 2002;168(2):621-6.
Fitch WP3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease - a placebo-controlled pilot study. J Sex Med. 2007;4(2):477-84.
Reich S, Altmeyer P, Stücker M. Systemic therapy of chronic venous diseases. Hautarzt. 2006;57(1):9-10,12-8.
Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capellà D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005;(3):CD003229.
Priollet P, Boisseau MR. Drugs for veno-lymphatic insufficiency. Rev Prat. 2000;50(11):1195-8.
Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol. 2009;7(3):303-8.
Badger C, Preston N, Seers K, Mortimer P. Benzopyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004;(2):CD003140.
Xu F, Zeng W, Mao X, Fan GK. The efficacy of melilotus extract in the management of postoperative ecchymosis and edema after simultaneous rhinoplasty and blepharoplasty. Aesthetic Plast Surg. 2008;32(4):599-603.
Godin B, Touitou E. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev. 2007;59(11):1152-61.
Minghetti P, Casiraghi A, Cilurzo F, Montanari L. Development of local patches containing melilot extract and ex vivo-in vivo evaluation of skin permeation. Eur J Pharm Sci. 2000;10(2):111-7.
Consoli A. Chronic venous insufficiency: an open trial of FLEBS Crema. Minerva Cardioangiol. 2003;51(4):411-6.
Pleşca-Manea L, Pârvu AE, Pârvu M, Taămaş M, Buia R, Puia M. Effects of Melilotus officinalis on acute inflammation. Phytother Res. 2002;16(4):316-19.
Zhao L, Tao JY, Zhang SL, Jin F, Pang R, Dong JH. Nbutanol extract from melilotus suaveolens ledeb affects pro- and anti-inflammatory cytokines and mediators. Evid Based Complement Alternat Med. 2007;14:1-10.
Tao JY, Zheng GH, Zhao L, Wu JG, Zhang XY, Zhang SL, et al. Anti-inflammatory effects of ethyl acetate fraction from melilotus suaveolens ledeb on LPSstimulated RAW 264.7 cells. J Ethnopharmacol. 2009;123(1):97-105.
Zhao L, Tao JY, Zhang SL, Pang R, Jin F, Dong JH, et al. Inner anti-inflammatory mechanisms of petroleum ether extract from Melilotus suaveolens Ledeb. Inflammation. 2007;30(6):213-23.
Belcaro G, Cesarone MR, Ledda A, Cacchio M, Ruffini I, Ricci A, et al. 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(betahydroxyethyl)-rutosides: a prospective comparative clinical registry. Angiology. 2008;59 Suppl 1:14S-20S.
Incandela L, Belcaro G, Renton S, DeSanctis MT, Cesarone MR, Bavera P, et al. HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther. 2002;7 Suppl 1:S7-S10.
Cesarone MR, Incandela L, DeSanctis MT, Belcaro G, Griffin M, Ippolito E, et al. Treatment of edema and increased capillary filtration in venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. J Cardiovasc Pharmacol Ther. 2002;7 Suppl 1:S21-4.
Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, et al. HR, 0-(beta-hydroxyethyl)-rutosides; (Venoruton): rapid relief of signs/symptoms in chronic venous insufficiency and microangiopathy: a prospective, controlled study. Angiology. 2005;56(2):165-72.
Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Di Renzo A, Vinciguerra G, et al. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study. Angiology. 2005;56(1):1-8.
Belcaro G, Cesarone MR, Ledda A, Cacchio M, Ruffini I, Ricci A, et al. O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study. Angiology. 2008;59 Suppl 1:7S-13S.
Vanscheidt W, Rabe E, Naser-Hijazi B, Ramelet AA, Partsch H, Diehm C, et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa. 2002;31(3):185-90
Celik A, Ersoy OF, Ozkan N, Kayaoglu HA, Ozugurlu F, Cakir EA, et al. Comparison of the effects of troxerutin and heparinoid on flap necrosis. J Plast Reconstr Aesthet Surg. 2009:[Epub ahead of print].
Laemmel E, Stücker O, Pons C, Duverger JP, Dedieu F, Leutenegger E. Microcirculatory consequences of a venous striction in the rat. Effect of a coumarine-rutine association. J Mal Vasc. 1998;23(3):176-82.
Wetzel D, Menke W, Dieter R, Smasal V, Giannetti B, Bulitta M. Escin/diethylammonium salicylate/heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study. Br J Sports Med. 2002;36(3):183-8.
Pabst H, Segesser B, Bulitta M, Wetzel D, Bertram S. Efficacy and tolerability of escin/diethylamine salicylate combination gels in patients with blunt injuries of the extremities. Int J Sports Med. 2001;22(6):430-6.
Cesarone MR, De Sanctis MT, Incandela L, Belcaro G, Griffin M. Microvascular changes in venous hypertension due to varicose veins after standardized application of Essaven gel--a placebo-controlled, randomized study. Angiology. 2001;52 Suppl 3:S11-6.
De Sanctis MT, Incandela L, Belcaro G, Cesarone MR. Topical treatment of venous microangiopathy in patients with venous ulceration with Essaven gel -a placebo-controlled, randomized study. Angiology. 2001;52 Suppl 3:S29-34.
De Sanctis MT, Cesarone MR, Incandela L, Belcaro G, Griffin M. Treatment of superficial vein thrombophlebitis of the arm with Essaven gel - a placebo-controlled, randomized study. Angiology. 2001;52 Suppl 3:S63-7.
Belcaro G, Cesarone MR, Dugall M. Microcirculatory efficacy of topical treatment with aescin + essential phospholipids gel in venous insufficiency and hypertension: new clinical observations. Angiology. 2004;55 Suppl 1:S1-5.
Cesarone MR, Belcaro G, Ippolito E, Ricci A, Ruffini M, Dugall M. Microcirculatory efficacy of topical treatment with aescin + essential phospholipids gel on transcutaneous PO2 in venous insufficiency. Angiology. 2004;55 Suppl 1:S7-10.
Ricci A, Ruffini I, Cesarone MR, Cornelli U, Corsi M, Belcaro G, Ippolito E, Dugall M. Variations in plasma free radicals with topical aescin + essential phospholipids gel in venous hypertension: new clinical data. Angiology. 2004;55 Suppl 1:S11-4.
Ruffini I, Belcaro G, Cesarone MR, Dugall M. Efficacy of topical treatment with aescin + essential phospholipids gel in venous insufficiency and hypertension. Angiology. 2004;55 Suppl 1:S19-21.
Misra MC, Imlitemsu. Drug treatment of haemorrhoids. Drugs. 2005;65(11):1481-91.
Koksal C, Bozkurt AK, Ustundag N, Konukoglu D, Musellim B, Sirin G, et al. Attenuation of acute lung injury following lower limb ischemia/reperfusion: the pharmacological approach. J Cardiovasc Surg (Torino). 2006;47(4):445-9.
Cuevas P, Sanchez I, Lozano RM, Gimenez-Gallego G. Dobesilate is an angiogenesis inhibitor. Eur J Med Res. 2005;10(9):369-72.
Iriz E, Vural C, Ereren E, Poyraz A, Erer D, Oktar L, et al. Effects of calcium dobesilate and diosmin-hesperidin on apoptosis of venous wall in primary varicose veins. Vasa. 2008;37(3):233-40.
Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capellà D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005;(3):CD003229.
Flota-Cervera F, Flota-Ruiz C, Treviño C, Berber A. Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology. 2008l;59(3):352-6.
Khadzhaĭ IaI, Chaĭka LA. Mechanism of the microcirculatory effects of ethyl-3,5,6-tri-O-benzyl-D-glucofuranoside. Farmakol Toksikol. 1983;46(2):72-5.
Downloads
Published
Issue
Section
License
Copyright (c) 2010 Acta Fisiátrica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
